| Literature DB >> 26917586 |
Susan Byrne1, Lara Jansen2, Jean-Marie U-King-Im3, Ata Siddiqui3, Hart G W Lidov4, Istvan Bodi5, Luke Smith6, Rachael Mein7, Thomas Cullup8, Carlo Dionisi-Vici9, Lihadh Al-Gazali10, Mohammed Al-Owain11, Zandre Bruwer12, Khalid Al Thihli12, Rana El-Garhy13, Kevin M Flanigan14, Kandamurugu Manickam15, Erik Zmuda15, Wesley Banks15, Ruth Gershoni-Baruch16, Hanna Mandel17, Efrat Dagan18, Annick Raas-Rothschild19, Hila Barash19, Francis Filloux20, Donnell Creel21, Michael Harris22, Ada Hamosh23, Stefan Kölker24, Darius Ebrahimi-Fakhari24, Georg F Hoffmann24, David Manchester25, Philip J Boyer26, Adnan Y Manzur27, Charles Marques Lourenco28, Daniela T Pilz29, Arveen Kamath29, Prab Prabhakar30, Vamshi K Rao31, R Curtis Rogers32, Monique M Ryan33, Natasha J Brown34, Catriona A McLean35, Edith Said36, Ulrike Schara37, Anja Stein38, Caroline Sewry39, Laura Travan40, Frits A Wijburg41, Martin Zenker42, Shehla Mohammed43, Manolis Fanto2, Mathias Gautel6, Heinz Jungbluth44.
Abstract
Vici syndrome is a progressive neurodevelopmental multisystem disorder due to recessive mutations in the key autophagy gene EPG5. We report genetic, clinical, neuroradiological, and neuropathological features of 50 children from 30 families, as well as the neuronal phenotype of EPG5 knock-down in Drosophila melanogaster. We identified 39 different EPG5 mutations, most of them truncating and predicted to result in reduced EPG5 protein. Most mutations were private, but three recurrent mutations (p.Met2242Cysfs*5, p.Arg417*, and p.Gln336Arg) indicated possible founder effects. Presentation was mainly neonatal, with marked hypotonia and feeding difficulties. In addition to the five principal features (callosal agenesis, cataracts, hypopigmentation, cardiomyopathy, and immune dysfunction), we identified three equally consistent features (profound developmental delay, progressive microcephaly, and failure to thrive). The manifestation of all eight of these features has a specificity of 97%, and a sensitivity of 89% for the presence of an EPG5 mutation and will allow informed decisions about genetic testing. Clinical progression was relentless and many children died in infancy. Survival analysis demonstrated a median survival time of 24 months (95% confidence interval 0-49 months), with only a 10th of patients surviving to 5 years of age. Survival outcomes were significantly better in patients with compound heterozygous mutations (P = 0.046), as well as in patients with the recurrent p.Gln336Arg mutation. Acquired microcephaly and regression of skills in long-term survivors suggests a neurodegenerative component superimposed on the principal neurodevelopmental defect. Two-thirds of patients had a severe seizure disorder, placing EPG5 within the rapidly expanding group of genes associated with early-onset epileptic encephalopathies. Consistent neuroradiological features comprised structural abnormalities, in particular callosal agenesis and pontine hypoplasia, delayed myelination and, less frequently, thalamic signal intensity changes evolving over time. Typical muscle biopsy features included fibre size variability, central/internal nuclei, abnormal glycogen storage, presence of autophagic vacuoles and secondary mitochondrial abnormalities. Nerve biopsy performed in one case revealed subtotal absence of myelinated axons. Post-mortem examinations in three patients confirmed neurodevelopmental and neurodegenerative features and multisystem involvement. Finally, downregulation of epg5 (CG14299) in Drosophila resulted in autophagic abnormalities and progressive neurodegeneration. We conclude that EPG5-related Vici syndrome defines a novel group of neurodevelopmental disorders that should be considered in patients with suggestive features in whom mitochondrial, glycogen, or lysosomal storage disorders have been excluded. Neurological progression over time indicates an intriguing link between neurodevelopment and neurodegeneration, also supported by neurodegenerative features in epg5-deficient Drosophila, and recent implication of other autophagy regulators in late-onset neurodegenerative disease.Entities:
Keywords: EPG5; Vici syndrome; callosal agenesis; ectopic P granules autophagy protein 5; neurodegeneration; neurodevelopment
Mesh:
Substances:
Year: 2016 PMID: 26917586 PMCID: PMC4766378 DOI: 10.1093/brain/awv393
Source DB: PubMed Journal: Brain ISSN: 0006-8950 Impact factor: 13.501
EPG5 mutations in patients with Vici syndrome
| Family | Origin | Ethnicity | Consanguinity | Mutation 1 | Mutation 2 | ||||
|---|---|---|---|---|---|---|---|---|---|
| Nucleotide | Amino acid | Exon | Nucleotide | Amino acid | Exon | ||||
| 1 | Italy | Caucasian | No | c.4588C>T | p.Gln1530* | 26 | c.5704dupT | p.Tyr1902Leufs*2 | 33 |
| 2 | Italy | Caucasian | No | c.2413-2A>G | c.6724delA | p.Met2242Cysfs*5 | 39 | ||
| 3 | UK | British-Asian | No | c.1253-1G>T | c.5110-1G>C | ||||
| 4 | Germany | Turkish | Yes | c.4952+1G>A | p.Phe1604Glyfs*20 | 28 | c.4952+1G>A | p.Phe1604Glyfs*20 | 28 |
| 5 | Netherlands | Turkish | Yes | c.3481C>T | p.Arg1161* | 19 | c.3481C>T | p.Arg1161* | 19 |
| 6 | USA | Caucasian | No | c.5835T>A | p.Cys1945* | 33 | c.1370T>C | p.Leu457Pro | 4 |
| c.2351A>C | p.Gln784Pro | 12 | |||||||
| 7 | USA | Caucasian | Yes | c.1007A>G | p.Gln336Arg | 2 | c.1007A>G | p.Gln336Arg | 2 |
| 8 | USA | Caucasian | No | c.2575G>T | p.Glu859* | 14 | c.6232C>T | p.Arg2078* | 37 |
| 9 | Saudi Arabia | Arabic | Yes | c.4751T>A | p.Leu1584* | 27 | c.4751T>A | p.Leu1584* | 27 |
| 10 | Japan | Japanese | No | c.2719-1G>A | c.6295dupA | p.Ser2099Lysfs*5 | 37 | ||
| 11 | Malta | Caucasian | No | c.6724delA | p.Met2242Cysfs*5 | 39 | c.6724delA | p.Met2242Cysfs*5 | 39 |
| 12 | USA | Caucasian | No | c.6005_6006dupAG | p.Leu2003Serfs*30 | 35 | c.6112T>C | p.Cys2038Arg | 36 |
| 13 | UAE | Arabic | Yes | c.4783C>T | p.Gln1595* | 27 | c.4783C>T | p.Gln1595* | 27 |
| 14 | Egypt | Arabic | Yes | c.2355delC | p.Arg786Glufs*10 | 12 | c.2355delC | p.Arg786Glufs*10 | 12 |
| 15 | Israel | Israeli-Arabic | Yes | c.5993C>G | p.Ser1998* | 35 | c. 5993C>G | p.Ser1998* | 35 |
| 16 | UK | Caucasian | No | c.1007A>G | p.Gln336Arg | 2 | ? | ? | |
| 17 | Germany | Turkish | Yes | c.1278delC | p.Ser427Leufs*6 | 4 | c.1278delC | p.Ser427Leufs*6 | 4 |
| 18 | Australia/Greece | Caucasian | Yes | c.7333C>T | p.Arg2445* | 42 | c.7333C>T | p.Arg2445* | 42 |
| 19 | UAE | Arabic | Yes | c.1249C>T | p.Arg417* | 3 | c.1249C>T | p.Arg417* | 3 |
| 20 | Italy | Caucasian | No | c.7447C>T | p.Arg2483* | 43 | c.1435_1438delCTTC | p.Leu479* | 5 |
| 21 | Oman | Arabic | Yes | c.6084G>A | p.Trp2028* | 36 | c.6084G>A | p.Trp2028* | 36 |
| 22 | Saudi Arabia | Arabic | Yes | c.3693G>A | p.Gln1231Gln | 20 | c.3693G>A | p.Gln1231Gln | 20 |
| 23 | Germany | Caucasian | No | c.5869+1G>A | c.5966G>A | p.Trp1989* | 35 | ||
| 24 | USA | Caucasian | No | c.136C>T | p.Gln46* | 2 | c.6275T>C | p.Leu2092Pro | 37 |
| 25 | Brazil | Caucasian | No | c.3481C>T | p.Arg1161* | 19 | c.6280delG | p.Glu2094Lysfs*23 | 37 |
| 26 | Israel | Ashkenazi | Yes | c.1007A>G | p.Gln336Arg | 2 | c.1007A>G | p.Gln336Arg | 2 |
| 27 | USA | Caucasian | No | c.2542delC | p.Gln848Argfs*25 | 13 | c.3493_3497delATCCT | p.Ile1165Leufs*8 | 19 |
| 28 | Israel | Israeli-Arabic | Yes | c.3447C>T | p.Trp1149* | 19 | c.3447C>T | p.Trp1149* | 19 |
| 29 | USA | Ashkenazi | No | c.1007A>G | p.Gln336Arg | 2 | c.1007A>G | p.Gln336Arg | 2 |
| 30 | USA | Caucasian | No | c.1249C>T | pArg417* | 3 | c.7240G>A | p.Glu2414Lys | 42 |
EPG5 mutations/variants described according to HGVS guidelines and transcript reference NM_020964.2. Stop mutations are indicated by an asterisk. EPG5 mutations in Families 1–13 have been previously reported in Cullup , EPG5 mutations in Families 14–30 are reported here for the first time. In Family 16, only one heterozygous pathogenic EPG5 variant was identified in the proband. The splicing change indicated in Family 4 was derived from cDNA sequencing. The c.3693G>A (p.Gln1231Gln) sequence variant identified in Family 22 occurs at the last base of the exon and is expected to cause aberrant splicing of the EPG5 transcript.
Figure 1Distribution of disease-causing mutations in The EPG5 gene is represented, with the 44 exons depicted as grey vertical bars (exons 1, 10, 25, 35 and 44 are numbered for orientation). The exon position of Vici-causing mutations are indicated by the arrows, with the mutation details listed at the arrow tail. Mutations found in two or more unrelated patients due to possible founder effects are coloured red. EPG5 mutations/variants described according to HGVS guidelines and transcript number NM_020964.2.
Clinical features of EPG5-related Vici syndrome
| Feature | % |
|---|---|
| Absent corpus callosum | 100 |
| Gross developmental delay | 100 |
| Immune problems | 100 |
| Failure to thrive | 97 |
| Pale skin/light hair | 95 |
| Microcephaly | 90 |
| Cardiomyopathy | 82 |
| Cataracts | 76 |
| Neonatal presentation | 87 |
| Seizures | 59 |
Clinical features and their relative frequencies compiled from genetically confirmed cases of Vici syndrome in this series (n = 38).
aOriginal diagnostic feature.
bNew diagnostic feature identified in this series.
Figure 2Clinical features of Clinical photographs from Patient 5.2 (A), Patient 3.1 (B), Patient 2.1 (C), shown with Professor Carlo Dionisi Vici, the original describer of Vici syndrome, Patient 23.1 (D), Patient 24.2 (E) and Patient 16.1 (F and G) at different ages. There is marked hypopigmentation, never absolute but always relative to the familial and ethnic background [Patient 5.2 (A) and Patient 3.1 (B) were of Turkish and British-Indian parentage, respectively]. Cataracts may be either present from birth (B, note reduced red reflex in the right eye) or develop over the first year of life. Some patients may have myopathic facial features (D, note tent-shaped mouth) and/or other clinical signs of a skeletal muscle myopathy. Few patients may have coarse facial features reminiscent of a lysosomal storage disorder, either present from birth (B) or developing with increasing age. Although head circumference is consistently normal at birth, all patients with EPG5-related Vici syndrome ultimately manifest microcephaly over time (C and E). In some patients, a recurrent, often confluent maculo-papular rash (F and G) was noted.
Figure 3Radiological features of (A) Midline sagittal T1 sequence showing complete agenesis of the corpus callosum. There is moderate-to-severe hypoplasia of the pons (arrow). In contrast, the cerebellar vermis appears well formed. (B) Axial T1 image at level of the body of the lateral ventricles show parallel configuration of the lateral ventricles (asterisk), typical for callosal agenesis. Moreover, the expected high T1 signal of myelin within the white matter is generally reduced (arrow), in keeping with delay in myelination. (C and D) Axial T1 and T2 at the level of the thalami show diffuse abnormal low T2 and high T1 signal within the thalamus (asterisk), a feature which has been reported in lysosomal storage disorders, but was only seen in a small proportion of our cases. There is also reduction in white matter bulk and reduced opercularization of Sylvian fissures (arrows). Note is made of colpocephaly with prominence of posterior horns of lateral ventricles (arrowheads), a feature seen with callosal agenesis.
Figure 4Ultrastructural abnormalities of muscle in Muscle biopsies from Patients 4.1 (A–B and D–F) and 27.1 (C). On electron microscopy, variability in fibre diameter (A) and central nuclei (A and B) often surrounded by a ‘ring-shaped’ mitochondrial arrangement (B) were noted. There was abundant intracellular debris (C), most commonly membrane-bound, often deposited within basal lamina layers (D) and with evidence of ongoing exocytosis. There was an increase in both free and membrane-bound glycogen in lysosomes (C and E). There was generalized reduction of often poorly formed myofilaments, admixed with deposited abnormal material (F).
Figure 5Neuropathological features of (A) Gross lateral view of left hemisphere. Note somewhat indistinct gyral pattern, and relatively prominent sulci for age. The insula is visible, consistent with an opercularization defect, and the Sylvian fissure extends more posteriorly than normal. (B) Whole-brain section stained with Luxol Fast blue/haematoxylin and eosin (LFB/H&E) at the level of the thalamus. Note the callosal agenesis, prominent temporal ventricles, and malrotated hippocampi. (C) Hippocampus immunostained for glial fibrillary acidic protein (GFAP). Most notable is the diminutive size of the fornix and associated reactive gliosis. (D) Transverse brainstem section at the level of the pons, stained with LFB/H&E. Note the small size of the pons, which is estimated to be less than half its normal volume. The superior cerebellar peduncles are relatively normal, as is the tegmentum, but the size of the medial lemniscus and corticospinal tracts are somewhat reduced, albeit less than the pontine grey matter.
Figure 6Knock-down of (A) Single confocal sections of fat bodies from fed and starved (6 h, unless otherwise indicated) larvae, either control or bearing RNAi-mediated downregulation of epg5. Red is membrane-bound RFP to highlight the cell membranes, green is the autophagy marker GFP::Atg8a. Arrows point to large autolysosomes from which GFP::Atg8a fluorescence is quenched on the inside, but is retained outside. Bottom left is a schematic drawing of an undigested fat body cell. (B) Semi-thin tangential eye sections from either control flies or flies bearing RNAi-mediated downregulation of epg5 and aged 1, 14, and 28 days at 29°C to induce epg5 downregulation. The drawing on top schematizes the process of cell degeneration and loss in this tissue. Below each section is an exemplary quantification of the photoreceptors in the ommatidia shown. (C) Graphs displaying the quantification of the number of photoreceptors (PR) in the ommatidia of the flies aged 14 and 28 days. Knock-down of epg5 reduces the ommatidia with a normal number of photoreceptor neurons (7) and this phenotype increases with time (χ2 values are 166.5 and 721.6 with P < 0.0001 for 6 degrees of freedom).